MUNICH, May 9, 2025 /PRNewswire/ — Sigenergy marked a key milestone during Intersolar 2025 with an exclusive launch event at Munich’s Brainlab Tower, reaffirming its commitment to building an AI-enhanced smart energy ecosystem. The event welcomed over 500 guests and underscored the company’s ambition to redefine the future of intelligent, user-centric energy systems.

Since its founding in 2022, Sigenergy has expanded rapidly into more than 60 countries, with strong market share gains across Europe, Africa, and Oceania in both residential and commercial segments, becoming one of the fastest growing companies in the industry.

” At Sigenergy, we believe energy systems should think, learn, and serve people,” said Tony Xu, Founder and CEO of Sigenergy. “We’re entering an era where autonomy and intelligence are not features, but fundamentals. That’s why we’re investing heavily in AI.”

One of the clearest expressions of Sigenergy’s investment in intelligence is the newly redesigned mySigen App 3.0. The app illustrates how AI is being seamlessly integrated to elevate the entire energy management experience. With features such as real-time visualized energy flows, a built-in AI assistant, and personalized usage analytics, it gives users sharper insights, smarter control, and the ability to optimize their energy usage with confidence.

Sigenergy’s customers-first philosophy is also emphasized in the event. “The smartest ideas often come from the people using our systems every day — installers, homeowners, and partners,” Xu said. “Innovation starts by listening.” By directly responding to user feedback, Sigenergy ensures that its hardware and software evolve to meet real-world needs, making them not only smarter but also easier to install, operate, and maintain.

The evening also celebrated the people behind Sigenergy’s rapid rise, with a Partner Awards Ceremony honoring top-performing distributors and installers. Their dedication and expertise have played a vital role in delivering Sigenergy’s smart energy solutions to more homes and businesses around the world.

SHANGHAI, May 9, 2025 /PRNewswire/ — Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (“Qilu”) for the development, manufacturing, and commercialization of its B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan).

Under the agreement, Qilu will obtain exclusive rights to MHB088C in the region, while Minghui will be eligible for total payments of up to 1.345 billion RMB, including: 280 million RMB upfront and a near-term milestone payment, 1.065 billion RMB in development, regulatory and sales milestone payments, and up to double-digit royalties on net product sales. Minghui will retain global rights to MHB088C outside Greater China and continue advancing its development in these regions.

MHB088C is an innovative B7-H3-targeted antibody-drug conjugate (ADC) developed using Minghui’s proprietary SuperTopoi™ ADC platform. It is distinguished by its potent anti-tumor activity and superior safety profile, significantly expanding the therapeutic window.

In ongoing Phase Ⅰ/Ⅱ clinical trials, MHB088C has been evaluated in over 300 patients with advanced or metastatic solid tumors, demonstrating a favorable safety profile and promising efficacy. Subgroup analyses in small cell lung cancer (SCLC) and metastatic castration-resistant prostate cancer (mCRPC) will be presented at the ASCO 2025 Annual Meeting as oral and poster presentations, respectively. A Phase Ⅲ trial in relapsed SCLC has been officially initiated in China, with the first patient being enrolled in a couple of weeks.

“Our collaboration with Qilu marks a significant milestone in Minghui’s commitment to advancing innovative cancer therapies,” said Dr. Guoqing Cao, CEO of Minghui. “MHB088C has demonstrated robust efficacy with great safety profiles, with no major hematological toxicity or ILD, positioning the program as a best-in-class B7-H3 ADC. With Qilu’s leadership and resources, we are confident that MHB088C will serve patients in need and contribute to the advancement of precision oncology in China.”

About Minghui Pharmaceutical
Minghui Pharmaceutical is a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address unmet medical needs in oncology and autoimmune diseases. With expertise in medical science and proprietary technology platforms, the company has built a diverse clinical-stage pipeline, including novel ADC programs and a PD-1xVEGF bispecific antibody. Minghui is committed to advancing breakthrough therapies that improve patient outcomes worldwide. For more information, please visit www.minghuipharma.com.

About Qilu Pharmaceutical
Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 3,6000 employees worldwide. Qilu ranks among Top 3 in Chinese pharmaceutical industry in 2024. Dedicated to offering high-quality & trustworthy medicines to the world and improving people’s well-being, Qilu is vigorously exporting its products to over 100 countries and regions around the world. To date, Qilu has launched over 300 products with over 55 products “First-to-Launch” in China. The company has also fostered a robust pipeline including over 200 generic products, over 20 biosimilars and over 80 innovative products.

Contact: Shiyu Zhou, syzhou@minghuipharma.com 

DUBAI, UAE, May 9, 2025 /PRNewswire/ — Yalla Group Limited (“Yalla” or the “Company”) (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced that it will report its unaudited financial results for the first quarter 2025 after the U.S. market closes on Monday, May 19, 2025.

Yalla Group Limited will hold a conference call on Monday, May 19, 2025, at 8:00 PM Eastern Time, 4:00 AM Dubai Time on Tuesday, May 20, 2025, or 8:00 AM Beijing Time on Tuesday, May 20, 2025, to discuss the financial results. Listeners may access the call by dialing the following numbers:

The replay will be accessible through May 26, 2025, by dialing the following numbers:

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.yalla.com.

About Yalla Group Limited

Yalla Group Limited is the largest MENA-based online social networking and gaming company, in terms of revenue in 2022. The Company operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games, popular in MENA, with in-game voice chat and localized Majlis functionality. Building on the success of Yalla and Yalla Ludo, the Company continues to add engaging new content, creating a regionally-focused, integrated ecosystem dedicated to fulfilling MENA users’ evolving online social networking and gaming needs. Through its holding subsidiary, Yalla Game Limited, the Company has expanded its capabilities in mid-core and hard-core games in the MENA region, leveraging its local expertise to bring innovative gaming content to its users. In addition, the growing Yalla ecosystem includes YallaChat, an IM product tailored for Arabic users, WeMuslim, a product that supports Arabic users in observing their customs, and casual games such as Yalla Baloot and 101 Okey Yalla, developed to sustain vibrant local gaming communities in MENA. Yalla is also actively exploring outside of MENA with Yalla Parchis, a Ludo game designed for the South American markets. Yalla’s mobile applications deliver a seamless experience that fosters a sense of loyalty and belonging, establishing highly devoted and engaged user communities through close attention to detail and localized appeal that profoundly resonates with users.

For more information, please visit https://ir.yalla.com.

Investor Relations Contact

Yalla Group Limited
Investor Relations
Kerry Gao – IR Director
Tel: +86-571-8980-7962
Email: ir@yalla.com

Piacente Financial Communications
Jenny Cai
Tel: +86-10-6508-0677
Email: yalla@tpg-ir.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: yalla@tpg-ir.com

HSINCHU, May 9, 2025 /PRNewswire-FirstCall/ — ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services (“OSAT”), today reported its unaudited consolidated revenue for the month of April 2025. All U.S. dollar figures cited in this press release are based on the exchange rate of NT$31.96 to US$1.00 as of April 30, 2025.

Revenue for the month of April 2025 was NT$1,860.8 million or US$58.2 million, representing a decrease of 8.4% from March 2025, and a decrease of 0.4% from April 2024. The Company noted that near-term results reflect broader industry trends.

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. (“ChipMOS” or the “Company”) (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) (www.chipmos.com) is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide. 

Forward-Looking Statements:

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future’ or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding tariffs, government policies, global trade environments, pricing, plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company’s most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s other filings with the SEC.

Contacts:

BEIJING, May 9, 2025 /PRNewswire/ — The 27th China Beijing International High-Tech Expo (The 27th CHITEC) officially opened on May 8 at the Beijing National Convention Center.

Themed “Science and Technology for A Better Future”, the exhibition covers a total area of approximately 50,000 square meters, featuring six major exhibition areas: Information Technology, Intelligent Manufacturing, Medicine and Health, Carbon Peaking and Carbon Neutrality, Digital Economy, and Regional Innovation. The Expo emphasizes the latest achievements in future industries, showcasing breakthroughs in cutting-edge technologies, cross-disciplinary innovation paradigms, and industrial application demonstrations that lead the acceleration of new quality productive forces formation. The Expo also highlights the achievements in building international innovation centers, featuring new scientific research outcomes, breakthroughs in frontier technologies, and collaborative innovations, thus injecting lasting momentum into high-quality development. The three trillion-level industrial clusters in Beijing are a major highlight, vividly showcasing breakthroughs in new applications of next-generation information technologies, the development of the pharmaceutical and health sectors, and new trends in the tech services industry.

Special emphasis is placed on how technology empowers new lifestyles, with a focus on high-quality consumer offerings. The role of AI in enhancing experiences is demonstrated, enriching the tech consumption landscape and making the event more interactive and engaging. The concept of “integrated exhibitions with virtual and physical fusion” is reflected in this year’s Expo, which continues to feature an online platform to offer exhibitors and visitors more diverse cooperation opportunities and value-added services, facilitating the pragmatic exchange of innovative solutions and the application of technological breakthroughs.

Furthermore, a series of trade and investment promotion activities are organized to foster collaboration across the industrial chain, drive win-win partnerships through innovation, and present high-quality industries on the global stage through efficient promotion.